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Abstract
© 2017, Pleiades Publishing, Ltd.Formyl peptide receptors (FPRs) expressed by mammalian
myeloid  cells  are  the  important  part  of  innate  immunity.  They  belong  to  the  seven-
transmembrane  domain  class  of  receptors  coupled  to  heterotrimeric  GTP-binding  proteins.
Binding of the receptor with a wide spectrum of exogenous and endogenous ligands triggers
such defensive phagocyte reactions as chemotaxis, secretory degranulation, and respiratory
burst, keeping a balance of inflammatory and antiinflammatory processes in the organism. The
association between single nucleotide polymorphisms in the gene of FPR1 receptor resulting in
disruption of the receptor structure and the development of certain pathologies accompanied
with inflammation, such as aggressive periodontitis, macular degeneration, and even gastric
cancer (Maney, P., and Walters, J. D. (2009) J. Periodontol., 80, 1498-1505; Liang, X. Y., et al.
(2014) Eye, 28, 1502-1510; Otani, T., et al. (2011) Biochem. Biophys. Res. Commun., 405, 356-
361) has been shown. In this review, we matched the missense mutation of formyl-peptide
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